Clearmind Schedules June 10 Webinar on Phase I/IIa CMND-100 Trial
CMND•Clearmind Medicine will host a live webinar on June 10, 2026 featuring early clinical data from its FDA-approved Phase I/IIa multi-center trial of CMND-100, a non-hallucinogenic MEAI oral candidate for Alcohol Use Disorder. Presenters include Yale’s Dr. Anahita Bassir Nia, Johns Hopkins’s Dr. Jennifer Ellis and CEO Adi Zuloff-Shani.
1. Webinar Details
Clearmind Medicine will host a free live webinar titled “Inside MEAI” on June 10, 2026 from 12:00–1:00 PM EDT. Interested participants can register via Eventbrite to join an exclusive investigator Q&A session.
2. Trial Overview
The webinar will present early findings from the FDA-approved Phase I/IIa multi-center trial evaluating CMND-100, Clearmind’s proprietary non-hallucinogenic, MEAI-based oral drug candidate for Alcohol Use Disorder. The session aims to review safety, tolerability and preliminary efficacy observations.
3. Speaker Lineup
Featured speakers include Dr. Anahita Bassir Nia of Yale School of Medicine and Dr. Jennifer Ellis of Johns Hopkins Medicine, both principal investigators on the trial, alongside Clearmind CEO Adi Zuloff-Shani, who will provide a clinical development and corporate update.
